RiboBio-B (06938.HK) Fully Exercised Over-Allotment Option, Stabilization Measures Completed and Stabilization Period Ended

Gelonghui, February 5th丨Ribo Bio-B (06938.HK) announced that the overall coordinator (for itself and on behalf of the international underwriters) has fully exercised the over-allotment option as described in the prospectus on February 5, 2026 (Thursday). This involves a total of 4,741,400 H shares (the "Over-Allotted Shares"), representing approximately 15% of the total number of offer shares available for subscription under the global offering before the exercise of any over-allotment option (after full exercise of the adjustment option). The Over-Allotted Shares will be issued by the company at a price of HKD 57.97 per H share (i.e., the issue price per H share under the global offering, excluding 1%).

Gelonghui FinanceFeb 5 22:36

Guosen Securities: The prosperity of the small nucleic acid CXO industry continues to rise, entering the phase of clinical validation and accelerated commercialization.

Priority should be given to CRO enterprises with core technologies such as chemical modification, delivery technology, conjugation technology, and extensive experience in small nucleic acid projects; as well as CDMO enterprises with forward-looking layouts and leading production capabilities.

Zhitong FinanceFeb 2 14:30

Hong Kong Stock IPO Monthly Report | January new stock success rate at 100%! MINIMAX surged over 109% on the first day, earning more than HKD 16,000 per lot for investors.

As of January 2026, the IPO market has remained robust, with all 13 new listings achieving gains on their debut day, setting an optimistic tone for the market throughout the year.

Futu NewsJan 30 14:06

Full steam ahead! In early 2026, major insurers such as Taikang, Ping An, and Xinhua allocated over 1 billion yuan of insurance capital to the south, aggressively acquiring shares in Hong Kong-listed AI and biomedicine IPOs.

①Since 2025, seven insurance capital entities have participated in cornerstone investments for 20 Hong Kong IPOs, with a subscription amount reaching 4.7 billion Hong Kong dollars; ②Investment areas focus on four major sectors: industrial raw materials, AI, biomedicine, and consumer goods; ③In terms of post-listing stock price performance, insurance capital participating in cornerstone subscriptions has generally achieved floating profits.

cls.cnJan 28 11:26

RiboBio-B (06938.HK): RBD5044 injection receives implied approval from the National Medical Products Administration for Phase II clinical trials.

Gelonghui, January 23rd ─ Ribo Biotech-B (06938.HK) announced that the RBD5044 injection, independently developed by the group, has received implied approval from the National Medical Products Administration of China for Phase II clinical trials. RBD5044 is an siRNA drug targeting APOC3. APOC3 is a protein almost exclusively synthesized in the liver and plays a crucial role in lipid metabolism. RBD5044 can address complications associated with hypertriglyceridemia, providing a therapeutic option for managing dyslipidemia.

Gelonghui FinanceJan 23 07:03

H-share Movement | Ruibo Bio-B (06938) rose over 3% before noon. The company’s pipeline has FIC potential and has already entered Phase 2 clinical trials.

RiboBio-B (06938) rose over 3% in the morning session. As of the time of writing, it was up 2.63%, trading at HKD 78.15, with a turnover of HKD 48.3137 million.

Zhitong FinanceJan 15 11:54